Bronchogen

About Bronchogen

Bronchogen is a peptide bioregulator targeting the bronchopulmonary system, studied for its ability to restore balance in lung tissue, bronchi, and overall respiratory function. Bioregulators are comprised of shorter amino acid chains than typical peptides, which lowers the risk of unwanted immune responses. Each bioregulator is tissue-specific and can bind to DNA to regulate gene expression in its target tissue. Whereas larger peptides mainly act through signaling pathways, bioregulators tend to normalize cellular function at the genetic level — activating or suppressing genes linked to repair, regeneration, and longevity — so their effects are more foundational and longer-lasting than standard peptides, which typically act only while present during administration.

Dosing & Reconstitution Guide

— Reconstitution & Protocol —

Reconstitute: Mix the vial with 3.0 mL (300 units) of bacteriostatic (BAC) water.
Administration: Subcutaneous injection.
Timing: Dose at bedtime, 2 hours after your last meal.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: 6 days on, 1 day off each week.
Cycle Length: 40-day cycle; may be repeated after a 3–6 month break.
Goal: Support bronchopulmonary tissue repair and respiratory function based on bioregulator research.

Frequency: Inject once daily, 6 consecutive days per week.

Phase	Dose	Syringe (U-100)
Days 1–7	500 mcg/day (6 days/week)	8 units (0.08 mL)
Days 8–40	2 mg/day (6 days/week)	30 units (0.30 mL)

Benefits

• Cellular Regeneration – Enhances repair of bronchial and pulmonary epithelial cells, promoting tissue resilience.
• Respiratory System Regulation – Supports normal functioning of lung tissue and bronchial passages by modulating cellular repair and regeneration.
• Chronic Bronchial Conditions – May aid in management of chronic bronchitis, asthma, and recurrent inflammatory processes of the bronchi.
• Pulmonary Rehabilitation – Used in recovery support following respiratory infections, toxic exposures, or after mechanical ventilation.
• Allergic & Inflammatory Disorders – Helps reduce the impact of inflammatory responses in the bronchial system.
• Age-Related Respiratory Decline – Investigated for its ability to maintain respiratory tissue structure and function in older populations.
• Post-Infection Recovery – Supports normalization of bronchial tissue after viral or bacterial respiratory illnesses.
• Anti-Inflammatory Effects – Helps balance inflammatory signaling, which may reduce airway irritation and hyperreactivity.
• Improved Oxygen Exchange – By maintaining structural integrity of bronchial pathways, it may indirectly support better oxygen intake.
• Gene Expression Modulation – Influences epigenetic regulation of proteins associated with tissue health, repair, and immune defense in the lungs.
• Immune Support – Strengthens local immune defenses of the respiratory tract, improving resilience to environmental stressors.
• Therapeutic Adjunct – Can complement conventional treatments for respiratory illnesses by enhancing natural tissue recovery and lowering relapse risk.

Research Sources

Citations for verification. Many studies are animal/in-vitro.

1. Khavinson VK. Peptides and ageing (monograph on peptide bioregulators, including bronchial epithelium peptides). Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906
2. Khavinson VK et al. Research on short peptide bioregulators and tissue-specific regulation of gene expression (peptide bioregulator reviews; see PubMed for “Khavinson peptide bioregulators”).
3. Clinical reports on bronchial peptide bioregulators in chronic bronchopulmonary disease are primarily published in Russian gerontology literature; peer-reviewed human data specific to Bronchogen remain limited.